Inhibition_NN of_IN the_DT MEK1/ERK_NP pathway_NN reduces_VBZ arachidonic_JJ acid_JJ release_NN independently_RB of_IN cPLA2_JJ phosphorylation_NN and_CC translocation_NN Abstract_NP |_SYM Background_NN |_SYM The_DT 85-kDa_JJ cytosolic_JJ phospholipase_NN A2_NP (_( cPLA2_NN )_) mediates_VBZ arachidonic_JJ acid_NN (_( AA_NP )_) release_NN in_IN MDCK_NP cells_NNS ._SENT Although_IN calcium_NN and_CC mitogen-activated_JJ protein_NN kinases_NNS regulate_VB cPLA2_NN ,_, the_DT correlation_NN of_IN cPLA2_JJ translocation_NN and_CC phosphorylation_NN with_IN MAPK_NP activation_NN and_CC AA_NP release_NN is_VBZ unclear_JJ ._SENT Results_NNS |_SYM MEK1_JJ inhibition_NN by_IN U0126_NP inhibited_VBD AA_NP release_NN in_IN response_NN to_TO ATP_NP and_CC ionomycin_NN ._SENT This_DT directly_RB correlated_VBN with_IN inhibition_NN of_IN ERK_NP activation_NN but_CC not_RB with_IN phosphorylation_NN of_IN cPLA2_NN on_IN Ser505_NP ,_, which_WDT was_VBD only_RB partially_RB inhibited_VBN by_IN ERK_NP inhibition_NN ._SENT Inhibition_NN of_IN AA_NP release_NN by_IN U0126_NP was_VBD still_RB observed_VBN when_WRB stoichiometric_JJ phosphorylation_NN of_IN cPLA2_NN on_IN Ser505_NP was_VBD maintained_VBN by_IN activating_VBG p38_NN with_IN anisomycin_NN ._SENT Translocation_NN kinetics_NNS of_IN wild-type_NN cPLA2_NN and_CC cPLA2_JJ containing_VBG S505A_NP or_CC S727A_NP mutations_NNS to_TO Golgi_NP were_VBD similar_JJ in_IN response_NN to_TO ATP_NP and_CC ionomycin_NN and_CC were_VBD not_RB affected_VBN by_IN U0126_NP ._SENT Conclusions_NNS |_SYM These_DT results_NNS suggest_VBP that_IN the_DT ability_NN of_IN cPLA2_NN to_TO hydrolyze_VB membrane_NN phospholipid_NN is_VBZ reduced_VBN by_IN inhibition_NN of_IN the_DT MEK1/ERK_NP pathway_NN and_CC that_IN the_DT reduction_NN in_IN activity_NN is_VBZ independent_JJ of_IN cPLA2_JJ phosphorylation_NN and_CC translocation_NN to_TO membrane_NN ._SENT The_DT results_NNS also_RB demonstrate_VBP that_IN cPLA2_NN mutated_VBN at_IN the_DT phosphorylation_NN sites_NNS Ser505_NP and_CC Ser727_NP translocated_VBD with_IN similar_JJ kinetic_JJ as_IN wild-type_NN cPLA2_NN ._SENT anisomycin_NN ,_, arachidonic_JJ acid_NN ,_, calcium_NN ,_, cytosolic_JJ phospholipase_NN A2_NP ,_, ERK_NP ,_, fluorescent_JJ proteins_NNS ,_, phosphorylation_NN ,_, MEK_NP ,_, U0126_NP ,_, translocation_NN ,_, Cytosolic_NP PLA2_NP specifically_RB hydrolyzes_VBZ sn-2_JJ arachidonate_NN from_IN phospholipid_NN providing_VBG the_DT precursors_NNS for_IN many_JJ different_JJ lipid_NN mediators_NNS including_VBG prostaglandins_NNS and_CC leukotrienes_NNS ._SENT These_DT lipid_NN metabolites_NNS play_VBP a_DT role_NN in_IN acute_JJ inflammatory_JJ responses_NNS and_CC also_RB regulate_VB normal_JJ physiological_JJ processes_NNS ._SENT Certain_JJ prostaglandins_NNS are_VBP required_VBN for_IN female_JJ reproduction_NN and_CC kidney_NN function_NN ._SENT Because_IN of_IN its_PP$ important_JJ role_NN in_IN controlling_VBG levels_NNS of_IN arachidonic_JJ acid_NN (_( AA_NP )_) ,_, much_JJ attention_NN has_VBZ been_VBN focused_VBN on_IN the_DT regulation_NN of_IN cPLA2_JJ activation_NN ,_, with_IN particular_JJ emphasis_NN on_IN the_DT role_NN of_IN its_PP$ phosphorylation_NN and_CC Ca2+-mediated_JJ translocation_NN ._SENT cPLA2_NN is_VBZ regulated_VBN by_IN controlling_VBG its_PP$ cellular_JJ localization_NN and_CC access_NN to_TO membrane-phospholipid_JJ substrate_NN ._SENT An_DT amino_NN terminal_NN ,_, calcium-dependent_JJ lipid_NN binding_VBG (_( CaLB_NP or_CC C2_NP )_) domain_NN regulates_VBZ Ca2+-mediated_JJ cPLA2_JJ translocation_NN to_TO intracellular_JJ membranes_NNS ._SENT In_IN vitro_NP ,_, membrane_NN docking_VBG via_IN the_DT C2_NP domain_NN is_VBZ necessary_JJ and_CC sufficient_JJ for_IN catalysis_NN and_CC release_NN of_IN AA_NP ._SENT Binding_VBG of_IN calcium_NN ions_NNS by_IN the_DT cPLA2_JJ C2_NP domain_NN is_VBZ essential_JJ for_IN the_DT lipid_NN association_NN in_IN vitro_NN and_CC translocation_NN in_IN vivo_RB ._SENT In_IN response_NN to_TO an_DT increase_NN in_RB [_SYM Ca2+]i_NP ,_, cPLA2_NN translocates_VBZ to_TO the_DT Golgi_NP and_CC ER_NP ,_, however_RB translocation_NN to_TO Golgi_NP occurs_VBZ at_IN a_DT lower_NN [_SYM Ca2+]i_NP ._SENT Protein_NN kinase_NN pathways_NNS play_VBP major_JJ roles_NNS in_IN cPLA2_JJ activation_NN ,_, and_CC regulation_NN by_IN the_DT mitogen-activated_JJ protein_NN kinase_NN kinase_NN (_( MEK_NP )_) /extracellular-signal_JJ regulated_JJ kinase_NN (_( ERK_NP )_) signaling_VBG pathway_NN has_VBZ received_VBN particular_JJ attention_NN ._SENT cPLA2_NN is_VBZ phosphorylated_JJ by_IN mitogen_NN activated_VBN protein_NN (_( MAP_NP )_) kinases_NNS ,_, including_VBG p42/p44_JJ ERKs_NNS and_CC p38_NN ,_, on_IN Ser505_NP in_IN vitro_NP and_CC in_IN response_NN to_TO receptor_NN stimulation_NN [_SYM ,-_NN ]_SYM ._SENT In_IN addition_NN to_TO phosphorylation_NN by_IN MAP_NP kinase_NN ,_, it_PP has_VBZ been_VBN shown_VBN that_IN cPLA2_NN is_VBZ also_RB phosphorylated_JJ on_IN Ser727_JJ by_IN MAPK-interacting_JJ kinase_NN I_PP (_( MNKI_NP )_) and_CC on_IN Ser515_NP by_IN calcium/calmodulin-dependent_JJ protein_NN kinase_NN II_NP ._SENT Phosphorylation_NN of_IN these_DT sites_NNS may_MD also_RB play_VB a_DT role_NN in_IN regulating_VBG cPLA2_JJ function_NN in_IN certain_JJ cell_NN models_NNS ._SENT Phosphorylation_NN of_IN Ser505_NP has_VBZ been_VBN extensively_RB studied_VBN because_IN it_PP is_VBZ readily_RB detected_VBN due_JJ to_TO a_DT characteristic_JJ electrophoretic_JJ mobility_NN shift_NN when_WRB analyzed_VBN by_IN SDS-PAGE_NP ._SENT The_DT importance_NN of_IN Ser505_NP phosphorylation_NN in_IN regulating_VBG cPLA2_NN has_VBZ been_VBN demonstrated_VBN in_IN different_JJ cells_NNS and_CC in_IN vitro_NN models_NNS by_IN using_VBG cPLA2_NN containing_VBG a_DT S505A_NP mutation_NN ._SENT However_RB ,_, the_DT mechanism_NN whereby_WRB Ser505_NP phosphorylation_NN regulates_VBZ cPLA2_JJ function_NN has_VBZ been_VBN elusive_JJ ._SENT In_IN vitro_NN studies_NNS have_VBP demonstrated_VBN that_IN dephosphorylated_JJ cPLA2_NN is_VBZ catalytically_RB active_JJ and_CC that_DT Ser505_NP phosphorylation_NN increases_VBZ activity_NN by_IN only_JJ ~30_NN percent_NN ._SENT In_IN contrast_NN ,_, cells_NNS expressing_VBG the_DT cPLA2_JJ S505A_NP mutation_NN fail_VBP to_TO release_VB AA_NP in_IN response_NN to_TO a_DT low_JJ dose_NN of_IN calcium_NN ionophore_NN ,_, but_CC release_VB similar_JJ amounts_NNS of_IN AA_NP as_IN cells_NNS expressing_VBG wild-type_NN cPLA2_NN in_IN response_NN to_TO high_JJ dose_NN ionophore_NN ._SENT From_IN these_DT studies_NNS ,_, it_PP has_VBZ been_VBN suggested_VBN that_IN cPLA2_JJ Ser505_NP phosphorylation_NN may_MD have_VB a_DT role_NN in_IN regulating_VBG translocation_NN ._SENT A_DT previous_JJ study_NN demonstrated_VBD translocation_NN of_IN cPLA2_JJ S505A_NP in_IN response_NN to_TO Ca2+_NP ionophore_NN ,_, but_CC did_VBD not_RB address_VB the_DT kinetics_NN of_IN translocation_NN ,_, translocation_NN in_IN response_NN to_TO a_DT physiological_JJ agonist_NN ,_, or_CC differences_NNS in_IN targeting_VBG ._SENT To_TO better_RBR understand_VB the_DT regulation_NN of_IN cPLA2_NN by_IN the_DT MEK1/ERK_NP pathway_NN and_CC Ca2+_NP ,_, we_PP investigated_VBD the_DT effect_NN of_IN MEK_NP inhibitors_NNS on_IN AA_NP release_NN ,_, cPLA2_JJ phosphorylation_NN of_IN Ser505_NP ,_, cPLA2_JJ translocation_NN kinetics_NNS ,_, and_CC [_SYM Ca2+]i_NP increase_NN in_IN Madin-Darby_NP canine_JJ kidney_NN (_( MDCK_NP )_) cells_NNS ._SENT We_PP found_VBD that_DT inhibition_NN of_IN MEK1_NP by_IN U0126_NP significantly_RB inhibited_VBD AA_NP release_NN and_CC this_DT was_VBD correlated_VBN with_IN inhibition_NN of_IN ERK_NP activation_NN ._SENT However_RB ,_, MEK_NP inhibition_NN only_RB partially_RB affected_VBN cPLA2_JJ phosphorylation_NN and_CC had_VBD no_DT effect_NN on_IN the_DT kinetics_NN of_IN Ca2+-mediated_JJ cPLA2_JJ translocation_NN to_TO membrane_NN ._SENT In_IN addition_NN ,_, using_VBG cells_NNS expressing_VBG wild-type_NN cPLA2_NN and_CC cPLA2_NN with_IN S505A_NP or_CC S727A_NP mutations_NNS ,_, it_PP was_VBD found_VBN that_IN translocation_NN kinetics_NNS and_CC membrane_NN targeting_VBG in_IN response_NN to_TO ATP_NP or_CC ionomycin_NN was_VBD similar_JJ to_TO wild-type_NN cPLA2_NN ._SENT These_DT data_NNS suggest_VBP that_IN MEK1_JJ inhibition_NN reduces_VBZ cPLA2_JJ catalytic_JJ activity_NN and_CC AA_NP release_NN independently_RB of_IN phosphorylation_NN and_CC translocation_NN ._SENT Effect_NN of_IN MEK_NP inhibition_NN on_IN AA_NP release_NN ,_, ERK_NP activation_NN ,_, and_CC cPLA2_JJ Ser505_JJ phosphorylation_NN |_SYM To_TO study_VB the_DT role_NN of_IN the_DT MEK1/ERK_NP pathway_NN in_IN cPLA2_JJ activation_NN ,_, quiesced_JJ MDCK_NP cells_NNS were_VBD treated_VBN with_IN the_DT MEK1_JJ inhibitor_NN U0126_NN ,_, and_CC the_DT effect_NN on_IN AA_NP release_NN ,_, ERK_NP activation_NN ,_, and_CC cPLA2_JJ gel_NN shift_NN determined_VBD ._SENT For_IN equivalence_NN with_IN the_DT imaging_NN studies_NNS ,_, cells_NNS expressing_VBG EGFP-cPLA2_NP were_VBD used_VBN in_IN all_DT experiments_NNS ._SENT EGFP-cPLA2_NP was_VBD expressed_VBN to_TO similar_JJ levels_NNS as_IN endogenous_JJ enzyme_NN but_CC did_VBD not_RB contribute_VB significantly_RB to_TO AA_NP release_NN in_IN stably_RB transfected_JJ cells_NNS ._SENT However_RB ,_, EGFP-cPLA2_NP is_VBZ functional_JJ since_IN it_PP dose-dependently_RB catalyzes_VBZ release_NN of_IN AA_NP when_WRB expressed_VBN in_IN cells_NNS that_WDT lack_VBP endogenous_JJ cPLA2_NN ,_, such_JJ as_IN Sf9_NP cells_NNS and_CC immortalized_VBN mouse_NN lung_NN fibroblasts_NNS from_IN cPLA2alpha_NN knock-out_JJ mice_NNS ._SENT In_IN order_NN to_TO enhance_VB AA_NP release_NN in_IN cells_NNS containing_VBG endogenous_JJ cPLA2_NN ,_, it_PP is_VBZ necessary_JJ to_TO over-express_VB the_DT enzyme_NN several_JJ fold_NN as_IN previously_RB reported_VBN ._SENT Cytosolic_NP PLA2_NP has_VBZ been_VBN shown_VBN to_TO mediate_VB Ca2+-induced_NP AA_NP release_NN in_IN MDCK_NP cells_NNS treated_VBN with_IN ATP_NP and_CC IONO_NP in_IN experiments_NNS using_VBG the_DT group_NN IV_NP cPLA2alpha-specific_JJ inhibitor_NN pyrrolidine-1_NN ._SENT To_TO measure_VB cPLA2_NN mediated_VBN AA_NP release_NN ,_, EGFP-cPLA2-transfected_NP MDCK_NP cells_NNS labeled_VBD with_IN [_SYM 3H]-AA_JJ were_VBD incubated_VBN with_IN 0.3_CD ,_, 1_CD or_CC 10_CD muM_NN U0126_NN for_IN 15_CD min_NN prior_JJ to_TO stimulation_NN with_IN 100_CD muM_NN ATP_NP ,_, 1_CD muM_NN IONO_NP ,_, or_CC 10_CD muM_NN IONO_NP ._SENT AA_NN release_NN was_VBD measured_VBN at_IN 3_CD min_NN because_IN we_PP have_VBP shown_VBN that_IN ATP-_NP and_CC IONO-stimulated_JJ AA_NP release_NN peaks_NNS between_IN 3_CD to_TO 5_CD min_NN post-stimulation_NN ._SENT Agonist-induced_NP AA_NP release_NN was_VBD inhibited_VBN dose-dependently_NN by_IN U0126_NP with_IN the_DT highest_JJS U0126_NN concentration_NN used_VBN (_( 10_CD muM_NN )_) reducing_VBG AA_NP release_NN by_IN 72_CD --_: 80_CD %_NN with_IN all_DT agonists_NNS ._SENT This_DT inhibition_NN was_VBD independent_JJ of_IN the_DT total_JJ amount_NN of_IN AA_NP released_VBD ,_, since_IN AA_NP release_NN stimulated_VBN by_IN 10_CD muM_NN IONO_NP was_VBD 3-fold_NN greater_JJR than_IN release_NN stimulated_VBN with_IN 1_CD muM_NN IONO_NP or_CC 100_CD muM_NN ATP_NP ,_, but_CC the_DT percent_NN inhibition_NN by_IN U0126_NP was_VBD similar_JJ ._SENT Treatment_NN of_IN MDCK_NP cells_NNS with_IN 30_CD muM_NN PD098059_NP ,_, a_DT less_RBR potent_JJ inhibitor_NN of_IN MEK_NP ,_, resulted_VBN in_IN a_DT ~50_JJ %_NN reduction_NN in_IN AA_NP release_NN in_IN response_NN to_TO 100_CD muM_NN ATP_NP ,_, 1_CD muM_NN IONO_NP ,_, and_CC 10_CD muM_NN IONO_NP (_( data_NN not_RB shown_VBN )_) ._SENT Thus_RB ,_, in_IN MDCK_NP cells_NNS ,_, MEK1_JJ inhibition_NN significantly_RB reduces_VBZ the_DT ability_NN of_IN cPLA2_NN to_TO hydrolyze_VB AA_NP from_IN membrane_NN phospholipids_NNS ._SENT Figure_NP 1_CD |_SYM Effect_NN of_IN MEK_NP inhibition_NN on_IN AA_NP release_NN ,_, ERK_NP inhibition_NN ,_, and_CC cPLA2_JJ Ser505_NP phosphorylation_NN Effect_NN of_IN MEK_NP inhibition_NN on_IN AA_NP release_NN ,_, ERK_NP inhibition_NN ,_, and_CC cPLA2_JJ Ser505_NP phosphorylation_NN (_( A_NP )_) EGFP-cPLA2-transfected_JJ cells_NNS were_VBD incubated_VBN with_IN the_DT indicated_JJ concentrations_NNS of_IN U0126_NP for_IN 15_CD min_NN prior_JJ to_TO stimulation_NN with_IN 100_CD muM_NN ATP_NP ,_, 1_CD muM_NN IONO_NP ,_, or_CC 10_CD muM_NN IONO_NP ._SENT AA_NN release_NN was_VBD assayed_VBN at_IN 3_CD min_NN ._SENT Results_NNS show_VBP the_DT average_JJ +-_NN SD_NN of_IN 3_CD experiments_NNS (_( error_NN bars_NNS are_VBP down_RB for_IN ATP_NP for_IN clarity_NN )_) ._SENT Protein_NN extracts_VBZ from_IN EGFP-cPLA2-transfected_JJ cells_NNS incubated_VBN with_IN the_DT indicated_JJ concentrations_NNS of_IN U0126_NP for_IN 15_CD min_NN prior_JJ to_TO stimulation_NN with_IN 100_CD muM_NN ATP_NP ,_, 1_CD muM_NN IONO_NP ,_, or_CC 10_CD muM_NN IONO_NP for_IN 3_CD min_NN were_VBD subjected_VBN to_TO immunoblotting_NN using_VBG (_( B_NP )_) anti-phospho-ERK_NP and_CC (_( C_NP )_) anti-cPLA2_JJ polyclonal_JJ antibodies_NNS ._SENT Results_NNS are_VBP from_IN 3_CD to_TO 5_CD independent_JJ experiments_NNS ._SENT Table_NP 1_CD |_SYM Inhibition_NN of_IN AA_NP release_NN by_IN 10_CD muM_NN U0126_NP See_NP "_`` Experimental_NP Procedures_NPS "_'' for_IN experimental_JJ conditions_NNS and_CC methods_NNS to_TO determine_VB AA_NP release_NN ._SENT Percent_NN inhibition_NN of_IN AA_NP release_NN after_IN 3_CD min_NN of_IN agonist_NN treatment_NN are_VBP average_JJ +-_NN S.D._NP for_IN N_NP experiments_NNS preformed_VBN in_IN duplicate_NN ._SENT The_DT effect_NN of_IN MEK1_JJ inhibition_NN on_IN activation_NN of_IN p42/p44_NP ERK_NP measured_VBD by_IN immunoblot_NN analysis_NN using_VBG phospho-specific_JJ antibodies_NNS in_IN cells_NNS treated_VBN with_IN U0126_NP and_CC stimulated_VBN as_IN above_RB was_VBD determined_VBN ._SENT Work_NN in_IN our_PP$ laboratory_NN has_VBZ shown_VBN that_DT recognition_NN of_IN ERK_NP by_IN anti-phospho-ERK_NP antibodies_NNS correlates_NNS with_IN an_DT increase_NN in_IN ERK_NP activity_NN ._SENT Interestingly_RB ,_, the_DT anti-phospho-ERK_NP immunoblots_NNS revealed_VBD that_IN ERKs_NP were_VBD constitutively_RB activated_VBN in_IN untreated_JJ ,_, quiesced_JJ MDCK_NP cells_NNS and_CC activation_NN was_VBD not_RB enhanced_VBN further_JJR by_IN ATP_NP or_CC IONO_NP (_( Fig._NN ,_, left_VBN panel_NN )_) ._SENT ERK_NN activation_NN was_VBD diminished_VBN by_IN increasing_VBG concentrations_NNS of_IN U0126_NP and_CC was_VBD quantitatively_RB inhibited_VBN after_IN 15_CD min_NN incubation_NN in_IN 10_CD muM_NN U0126_NP ._SENT U0126_NP decreased_VBD ERK_NP activation_NN following_VBG ATP_NP or_CC IONO_NP stimulation_NN in_IN the_DT same_JJ fashion_NN as_IN in_IN unstimulated_JJ cells_NNS ._SENT Consequently_RB ,_, there_EX was_VBD a_DT direct_JJ correlation_NN between_IN the_DT reduction_NN of_IN AA_NP release_NN and_CC inhibition_NN of_IN ERK_NP activation_NN in_IN MDCK_NP cells_NNS treated_VBN with_IN U0126_NP ._SENT Because_IN cPLA2_NN is_VBZ a_DT target_NN of_IN the_DT MEK1/ERK_NP signaling_VBG cascade_NN ,_, we_PP assayed_VBD the_DT effect_NN of_IN MEK1_JJ inhibition_NN by_IN U0126_NP on_IN cPLA2_JJ phosphorylation_NN by_IN analyzing_VBG gel_NN shift_NN of_IN cPLA2_NN ._SENT Phosphorylation_NN of_IN Ser505_NP results_NNS in_IN a_DT retardation_NN of_IN its_PP$ electrophoretic_JJ mobility_NN (_( gel_NN shift_NN )_) ._SENT In_IN unstimulated_JJ cells_NNS ,_, EGFP-tagged_JJ and_CC endogenous_JJ cPLA2_NN were_VBD nearly_RB completely_RB gel_VB shifted_VBN ,_, indicating_VBG that_IN most_JJS cPLA2_NN was_VBD phosphorylated_JJ on_IN Ser505_NP ,_, which_WDT is_VBZ consistent_JJ with_IN the_DT observation_NN that_IN ERKs_NNS are_VBP constitutively_RB activated_VBN ._SENT Incubation_NN with_IN U0126_NP resulted_VBD in_IN a_DT partial_JJ reversal_NN of_IN the_DT gel_NN shift_NN although_IN ,_, at_IN 10_CD muM_NN U0126_NN ,_, approximately_RB half_NN of_IN cPLA2_NN remained_VBD phosphorylated_JJ on_IN Ser505_NP ._SENT Thus_RB ,_, unlike_IN the_DT quantitative_JJ effect_NN of_IN U0126_NP on_IN ERK_NP activation_NN ,_, inhibition_NN of_IN MEK1_NP with_IN U0126_NP only_RB partially_RB reversed_VBD the_DT gel_NN shift_NN of_IN cPLA2_NN ._SENT The_DT reversal_NN of_IN the_DT gel_NN shift_NN was_VBD similar_JJ in_IN cells_NNS treated_VBN with_IN ATP_NP and_CC 1_CD and_CC 10_CD muM_NN IONO_NP ._SENT Due_JJ to_TO the_DT increased_VBN molecular_JJ weight_NN of_IN the_DT EGFP-tagged_JJ cPLA2_NN ,_, the_DT two_CD forms_NNS of_IN cPLA2_NN did_VBD not_RB separate_VB as_RB well_RB ,_, making_VBG the_DT gel_NN shift_NN more_RBR difficult_JJ to_TO visualize_VB ,_, but_CC generally_RB mirrored_VBD the_DT gel_NN shift_NN characteristics_NNS of_IN the_DT endogenous_JJ cPLA2_NN ._SENT These_DT results_NNS suggest_VBP that_IN ,_, in_IN response_NN to_TO MEK1_JJ inhibition_NN ,_, there_EX is_VBZ a_DT quantitative_JJ ,_, dose-dependent_JJ decrease_NN in_IN AA_NP release_NN that_WDT correlates_VBZ well_RB with_IN the_DT loss_NN of_IN ERK_NP activation_NN ,_, but_CC not_RB with_IN the_DT extent_NN of_IN cPLA2_JJ Ser505_NP phosphorylation_NN ._SENT To_TO further_RBR investigate_VB whether_IN the_DT MEK1/ERK_NP pathway_NN played_VBD a_DT role_NN in_IN regulating_VBG AA_NP release_NN independent_JJ of_IN Ser505_NP phosphorylation_NN ,_, we_PP treated_VBD cells_NNS with_IN anisomycin_NN ,_, which_WDT activates_VBZ the_DT MAPK_NP homolog_NN p38_NN ,_, but_CC not_RB the_DT MEK1/ERK_NP pathway_NN ._SENT Activation_NN of_IN p38_NN in_IN response_NN to_TO anisomycin_NN treatment_NN was_VBD analyzed_VBN by_IN immunoblotting_NN using_VBG an_DT anti-phospho-p38_JJ antibody_NN ._SENT The_DT immunoblots_NNS demonstrate_VBP that_IN 30_CD min_NN treatment_NN in_IN 25_CD ng/ml_NNS anisomycin_NN resulted_VBD in_IN phosphorylation_NN of_IN p38_NN in_IN unstimulated_JJ MDCK_NP cells_NNS and_CC in_IN cells_NNS treated_VBN with_IN ATP_NP or_CC IONO_NP ._SENT ATP_NP and_CC ionomycin_NN treatment_NN in_IN the_DT absence_NN of_IN anisomycin_NN only_RB weakly_RB increased_VBN p38_JJ phosphorylation_NN ._SENT As_IN expected_VBN ,_, the_DT MEK_NP inhibitor_NN U0126_NP did_VBD not_RB significantly_RB affect_VB anisomycin-stimulated_JJ p38_NN phosphorylation_NN ._SENT In_IN control_NN experiments_NNS ,_, anisomycin_NN treatment_NN did_VBD not_RB induce_VB ERK_NP activation_NN nor_CC interfere_VB with_IN inhibition_NN of_IN ERK_NP activation_NN by_IN 10_CD muM_NN U0126_JJ treatment_NN ._SENT We_PP have_VBP previously_RB reported_VBN that_IN p38_NN is_VBZ also_RB selectively_RB activated_VBN in_IN anisomycin-treated_JJ macrophages_NNS ._SENT Importantly_RB ,_, pretreatment_NN of_IN cells_NNS for_IN 30_CD min_NN with_IN anisomycin_NN resulted_VBN in_IN maintenance_NN of_IN the_DT cPLA2_JJ gel_NN shift_NN in_IN the_DT presence_NN of_IN U0126_NP in_IN unstimulated_JJ cells_NNS and_CC in_IN cells_NNS stimulated_VBN with_IN ATP_NP and_CC 1_CD and_CC 10_CD muM_NN IONO_NP ._SENT AA_NN release_NN assays_NNS show_VBP that_IN ,_, in_IN MDCK_NP cells_NNS treated_VBN with_IN anisomycin_NN ,_, U0126_NP resulted_VBD in_IN an_DT AA_NP release_NN reduction_NN of_IN ~67_JJ --_: 76_CD %_NN similar_JJ to_TO the_DT inhibition_NN observed_VBD without_IN anisomycin_NN ._SENT These_DT results_NNS demonstrate_VBP that_IN activation_NN of_IN the_DT MEK1/ERK_NP pathway_NN is_VBZ required_VBN for_IN AA_NP release_NN even_RB under_IN conditions_NNS where_WRB cPLA2_JJ Ser505_NP phosphorylation_NN is_VBZ maintained_VBN ,_, suggesting_VBG an_DT alternative_JJ role_NN for_IN the_DT MEK1/ERK_NP pathway_NN in_IN regulating_VBG cPLA2_NN ._SENT Figure_NP 2_CD |_SYM Effect_NN of_IN anisomycin_NN and_CC U0126_NP on_IN AA_NP release_NN ,_, ERK_NP inhibition_NN ,_, and_CC cPLA2_JJ Ser505_NP phosphorylation_NN Effect_NN of_IN anisomycin_NN and_CC U0126_NP on_IN AA_NP release_NN ,_, ERK_NP inhibition_NN ,_, and_CC cPLA2_JJ Ser505_NP phosphorylation_NN EGFP-cPLA2-transfected_JJ cells_NNS were_VBD incubated_VBN with_IN 25_CD ng/ml_NNS anisomycin_JJ for_IN 30_CD min_NN ,_, 10_CD muM_NN U0126_NN for_IN 15_CD min_NN ,_, or_CC with_IN both_DT drugs_NNS prior_RB to_TO stimulation_NN with_IN 100_CD muM_NN ATP_NP ,_, 1_CD muM_NN IONO_NP ,_, or_CC 10_CD muM_NN IONO_NP ._SENT Protein_NN extracts_VBZ were_VBD subjected_VBN to_TO immunoblotting_NN using_VBG (_( A_NP )_) anti-phospho-p38_NP ,_, (_( B_NP )_) anti-phospho-ERK_NP ,_, and_CC (_( C_NP )_) anti-cPLA2_NN antibodies_NNS ._SENT (_( D_NP )_) AA_NP release_NN in_IN response_NN to_TO 100_CD muM_NN ATP_NP ,_, 1_CD muM_NN IONO_NP ,_, or_CC 10_CD muM_NN IONO_NP in_IN the_DT presence_NN and_CC absence_NN of_IN the_DT inhibitors_NNS ._SENT Anisomycin_NP did_VBD not_RB stimulate_VB AA_NP release_NN in_IN unstimulated_JJ cells_NNS ._SENT The_DT results_NNS show_VBP average_JJ +-_NN SEM_NP for_IN 3_CD to_TO 5_CD independent_JJ experiments_NNS ._SENT [_SYM Ca2+]i_NP increase_NN is_VBZ independent_JJ of_IN MEK1/ERK_JJ pathway_NN |_SYM One_CD explanation_NN for_IN the_DT decrease_NN in_IN AA_NP is_VBZ that_IN U0126_NP inhibits_VBZ [_SYM Ca2+]i_NP mobilization_NN in_IN response_NN to_TO ATP_NP or_CC IONO_NP ,_, thereby_RB preventing_VBG translocation_NN of_IN cPLA2_NN ._SENT In_IN chick_NN ventricular_JJ myocytes_NNS ,_, inhibition_NN of_IN MEK1/ERK_NP by_IN PD98059_NP inhibits_VBZ zinterol-mediated_JJ AA_NP release_NN ,_, but_CC also_RB inhibits_VBZ zinterol-induced_JJ stimulation_NN of_IN [_SYM Ca2+]i_NP cycling_NN in_IN electrically_RB stimulated_VBN cells_NNS ._SENT In_IN MDCK_NP cells_NNS ,_, extracellular_JJ ATP_NP acts_NNS via_IN P2Y2_JJ receptors_NNS to_TO elicit_VB an_DT IP3-mediated_NN [_SYM Ca2+]i_NP increase_NN and_CC IONO_NP acts_VBZ to_TO increase_NN [_SYM Ca2+]i_NP by_IN permeabilizing_VBG cell_NN membranes_NNS to_TO Ca2+_NP ._SENT To_TO determine_VB the_DT effect_NN of_IN U0126_NP on_IN intracellular_JJ Ca2+_NP mobilization_NN by_IN 100_CD muM_NN ATP_NP or_CC 10_CD muM_NN IONO_NP ,_, we_PP utilized_VBD single-cell_NN fluorescence_NN microscopy_NN on_IN cells_NNS loaded_VBN with_IN the_DT calcium_NN indicator_NN Fura2_NP ._SENT Analysis_NN of_IN the_NP [_SYM Ca2+]i_NP increase_NN in_IN individual_JJ cells_NNS reveals_VBZ the_DT heterogeneity_NN in_IN the_DT response_NN to_TO ATP_NP ,_, although_IN most_JJS cells_NNS exhibited_VBN [_SYM Ca2+]i_NP spikes_NNS of_IN similar_JJ magnitude_NN and_CC duration_NN (_( Fig._NN and_CC ,_, thin_JJ lines_NNS )_) ._SENT Analysis_NN of_IN the_NP [_SYM Ca2+]i_NP increase_NN in_IN several_JJ cells_NNS (_( Fig._NN and_CC ,_, thick_JJ line_NN )_) revealed_VBD that_IN although_IN the_DT duration_NN of_IN the_NP [_SYM Ca2+]i_NP increase_NN elicited_VBN by_IN ATP_NP in_IN control_NN cells_NNS was_VBD the_DT same_JJ as_RB in_IN the_DT U0126-treated_JJ cells_NNS ,_, approximately_RB 3_CD --_: 4_CD min_NN ,_, the_DT amplitude_NN of_IN the_NP [_SYM Ca2+]i_NP increase_NN was_VBD slightly_RB higher_JJR (_( ~20_JJ %_NN )_) in_IN the_DT U0126-treated_JJ cells_NNS ._SENT IONO_NP elicited_VBD a_DT sustained_JJ ,_, supraphysiological_NN [_SYM Ca2+]i_NP increase_NN in_IN cells_NNS that_WDT was_VBD also_RB slightly_RB enhanced_VBN by_IN U0126_NP (_( Fig._NN and_CC )_) ._SENT These_DT experiments_NNS demonstrate_VBP that_IN U0126_NP does_VBZ not_RB decrease_NN [_SYM Ca2+]i_NP mobilization_NN ,_, and_CC the_DT inhibition_NN of_IN AA_NP release_NN by_IN U0126_NP cannot_MD be_VB ascribed_VBN to_TO a_DT failure_NN in_RB [_SYM Ca2+]i_NP mobilization_NN ._SENT Figure_NP 3_CD |_SYM Effect_NN of_IN U0126_NP on_IN ATP-_NP and_CC IONO-induced_NP [_SYM Ca2+]i_NP change_NN Effect_NN of_IN U0126_NP on_IN ATP-_NP and_CC IONO-induced_NP [_SYM Ca2+]i_NP change_VB MDCK_NP cells_NNS were_VBD loaded_VBN with_IN the_DT fluorescent_JJ Ca2+_NP indicator_NN Fura2_NP ,_, incubated_VBN with_IN 10_CD muM_NN U0126_NN or_CC vehicle_NN for_IN 15_CD min_NN ,_, and_CC stimulated_VBN with_IN 100_CD muM_NN ATP_NP or_CC 10_CD muM_NN IONO_NP ._SENT Graphs_NNS show_VBP changes_NNS in_RB [_SYM Ca2+]i_NP (_( expressed_VBN as_IN the_DT 340/380_CD ratio_NN of_IN Fura2_NP fluorescence_NN )_) with_IN respect_NN to_TO time_NN from_IN 8_CD individual_JJ cells_NNS (_( thin_JJ traces_NNS )_) and_CC from_IN the_DT average_NN of_IN 16_CD cells_NNS (_( thick_JJ trace_NN )_) treated_VBN with_IN (_( A_NP )_) U0126_NP and_CC ATP_NP ,_, (_( B_NP )_) vehicle_NN and_CC ATP_NP ,_, (_( C_NP )_) U0126_NP and_CC IONO_NP ,_, and_CC (_( D_NP )_) vehicle_NN and_CC IONO_NP ._SENT Results_NNS are_VBP representative_JJ of_IN 4_CD independent_JJ experiments_NNS in_IN each_DT condition_NN and_CC analysis_NN of_IN several_JJ cells_NNS per_IN experiment_NN ._SENT cPLA2_JJ translocation_NN is_VBZ independent_JJ of_IN MEK1/ERK_JJ pathway_NN |_SYM The_DT effect_NN of_IN inhibition_NN of_IN the_DT MEK1/ERK_NP pathway_NN by_IN U0126_NP on_IN translocation_NN of_IN cPLA2_NN was_VBD investigated_VBN ._SENT Although_IN there_EX is_VBZ no_DT inhibition_NN of_IN [_SYM Ca2+]i_NP release_NN by_IN U0126_NP and_CC little_JJ effect_NN on_IN Ser505_NP phosphorylation_NN ,_, it_PP is_VBZ possible_JJ that_IN MEK1_JJ inhibition_NN by_IN U0126_NP prevents_VBZ cPLA2_JJ translocation_NN by_IN another_DT mechanism_NN ._SENT To_TO investigate_VB this_DT possibility_NN ,_, cells_NNS were_VBD transfected_VBN with_IN a_DT wild-type_NN cPLA2_NN fused_VBD to_TO EYFP_NP (_( EYFP-cPLA2_NP )_) and_CC the_DT distribution_NN of_IN EYFP-cPLA2_NP was_VBD imaged_VBN in_IN response_NN to_TO [_SYM Ca2+]i_NP transients_NNS elicited_VBN by_IN ATP_NP and_CC sustained_VBN [_SYM Ca2+]i_NP elevations_NNS elicited_VBN by_IN IONO_NP ,_, in_IN the_DT presence_NN and_CC absence_NN of_IN U0126_NP ._SENT Following_VBG stimulation_NN with_IN 100_CD muM_NN ATP_NP ,_, there_EX was_VBD a_DT rapid_JJ translocation_NN of_IN EYFP-cPLA2_NP to_TO Golgi_NP that_WDT was_VBD unaffected_JJ by_IN U0126_NP ._SENT In_IN response_NN to_TO physiological_JJ agonists_NNS that_WDT elicit_VBP transient_NN [_SYM Ca2+]i_NP changes_NNS ,_, only_RB a_DT small_JJ fraction_NN of_IN the_DT cPLA2_NN translocates_VBZ ._SENT This_DT observation_NN is_VBZ consistent_JJ with_IN our_PP$ previous_JJ results_NNS and_CC has_VBZ been_VBN demonstrated_VBN by_IN Hirabayashi_NP et_FW al._FW ._SENT Most_JJS studies_NNS of_IN cPLA2_JJ translocation_NN have_VBP utilized_VBN ionophore_NN ,_, which_WDT elicits_VBZ a_DT large_JJ ,_, supraphysiological_JJ sustained_JJ increase_NN in_RB [_SYM Ca2+]i[,,,-_NP ]_SYM ,_, or_CC agonists_NNS that_WDT produce_VBP a_DT sustained_VBN [_SYM Ca2+]i_NP increase_NN ._SENT Under_IN these_DT conditions_NNS ,_, a_DT large_JJ proportion_NN of_IN cPLA2_JJ binds_NNS to_TO membrane_NN ._SENT These_DT studies_NNS show_VBP extensive_JJ translocation_NN to_TO the_DT endoplasmic_JJ reticulum_NN (_( ER_NP )_) ,_, nuclear_JJ envelope_NN and_CC Golgi_NP ._SENT We_PP found_VBD that_IN U0126_NP also_RB failed_VBD to_TO alter_VB extensive_JJ EYFP-cPLA2_JJ translocation_NN to_TO Golgi_NP and_CC ER_NP in_IN response_NN 10_CD muM_NN IONO_NP ._SENT These_DT results_NNS demonstrate_VBP that_IN MEK_NP inhibition_NN has_VBZ no_DT effect_NN on_IN cPLA2_JJ translocation_NN ._SENT Figure_NP 4_CD |_SYM Effect_NN of_IN U0126_NP on_IN translocation_NN of_IN EYFP-cPLA2_NP following_VBG ATP_NP or_CC IONO_NP stimulation_NN Effect_NN of_IN U0126_NP on_IN translocation_NN of_IN EYFP-cPLA2_NP following_VBG ATP_NP or_CC IONO_NP stimulation_NN Cells_NP expressing_VBG EYFP-cPLA2_NP were_VBD incubated_VBN with_IN 10_CD muM_NN U0126_NP (_( B_NP ,_, D_NP )_) or_CC vehicle_NN (_( A_NP ,_, C_NP )_) for_IN 15_CD min_NN prior_JJ to_TO stimulation_NN with_IN 100_CD muM_NN ATP_NP (_( A_NP ,_, B_NP )_) or_CC 10_CD muM_NN IONO_NP (_( C_NP ,_, D_NP )_) ._SENT Representative_JJ frames_NNS from_IN time-lapse_NN images_NNS show_VBP the_DT distribution_NN of_IN EYFP-cPLA2_JJ fluorescence_NN before_IN and_CC after_IN stimulation_NN ._SENT Results_NNS are_VBP representative_JJ of_IN 4_CD independent_JJ experiments_NNS and_CC analysis_NN of_IN several_JJ cells_NNS per_IN experiment_NN ._SENT Translocation_NN of_IN phosphorylation_NN site_NN mutants_NNS S505A_NP or_CC S727A_NP is_VBZ similar_JJ as_IN wild-type_JJ cPLA2_NN |_SYM Phosphorylation_NN of_IN cPLA2_NN on_IN Ser505_NP has_VBZ been_VBN hypothesized_VBN to_TO play_VB a_DT role_NN in_IN Ca2+-mediated_JJ translocation_NN since_IN Ser505_NP phosphorylation_NN is_VBZ required_VBN for_IN cPLA2-mediated_JJ AA_NP release_NN in_IN response_NN to_TO low-dose_NN ,_, but_CC not_RB high-dose_NN ,_, ionophore_NN ._SENT Translocation_NN of_IN cPLA2_JJ S505A_NP in_IN CHO_NP cells_NNS has_VBZ been_VBN reported_VBN in_IN response_NN to_TO ionophore_NN stimulation_NN ,_, but_CC the_DT effect_NN of_IN Ser505_NP phosphorylation_NN on_IN the_DT kinetics_NN of_IN translocation_NN ,_, targeting_VBG ,_, and_CC in_IN response_NN to_TO a_DT physiological_JJ agonist_NN was_VBD not_RB investigated_VBN ._SENT MDCK_NP cells_NNS were_VBD co-transfected_VBN with_IN EYFP-cPLA2_NP and_CC a_DT cPLA2_NN with_IN a_DT S505A_NP mutation_NN fused_VBD to_TO ECFP_NP (_( ECFP-cPLA2S505A_NP )_) ._SENT Using_VBG dual_JJ EYFP/ECFP_NP imaging_NN ,_, we_PP were_VBD able_JJ to_TO directly_RB compare_VB translocation_NN of_IN both_DT constructs_NNS in_IN the_DT same_JJ cell_NN ._SENT The_DT resting_JJ distribution_NN of_IN EYFP-cPLA2_NP was_VBD similar_JJ to_TO that_DT of_IN ECFP-cPLA2S505A_NP and_CC ,_, in_IN response_NN to_TO ATP_NP followed_VBN by_IN IONO_NP ,_, the_DT pattern_NN of_IN translocation_NN of_IN EYFP-cPLA2_NP was_VBD similar_JJ to_TO ECFP-cPLA2S505A_NP (_( Fig._NN panels_NNS A_NP and_CC B_NP ,_, D_NP )_) ._SENT Analysis_NN of_IN the_DT increase_NN in_IN fluorescence_NN at_IN the_DT Golgi_NP with_IN respect_NN to_TO time_NN demonstrates_VBZ that_IN the_DT rates_NNS of_IN translocation_NN of_IN cPLA2_NN and_CC cPLA2S505A_NN elicited_VBN by_IN ATP_NP followed_VBD by_IN IONO_NP are_VBP very_RB similar_JJ ._SENT As_IN previously_RB reported_VBN ,_, the_DT cPLA2_JJ S727A_NP mutation_NN has_VBZ a_DT similar_JJ phenotype_NN on_IN AA_NP release_NN as_IN the_DT S505A_NP mutation_NN and_CC Ser727_JJ was_VBD found_VBN to_TO be_VB phosphorylated_JJ in_IN tandem_NN with_IN Ser505_NP ._SENT Imaging_NN experiments_NNS were_VBD performed_VBN using_VBG EYFP-cPLA2_NP and_CC ECFP-cPLA2S727A_NP and_CC we_PP found_VBD that_IN the_DT distribution_NN of_IN EYFP-cPLA2_NP was_VBD identical_JJ to_TO that_DT of_IN ECFP-cPLA2S727A_NP before_IN and_CC after_IN stimulation_NN with_IN 10_CD muM_NN IONO_NP (_( Fig._NN 7_CD panels_NNS A_NP and_CC B_NP ,_, D_NP )_) ._SENT Analysis_NN of_IN the_DT increase_NN in_IN fluorescence_NN at_IN the_DT Golgi_NP with_IN respect_NN to_TO time_NN demonstrates_VBZ that_IN the_DT rates_NNS of_IN translocation_NN of_IN cPLA2_NN and_CC the_DT cPLA2S727A_NN elicited_VBN by_IN IONO_NP are_VBP very_RB similar_JJ ._SENT Figure_NP 5_CD |_SYM Translocation_NN of_IN ECFP-cPLA2S505A_NP following_VBG ATP_NP and_CC IONO_NP stimulation_NN Translocation_NN of_IN ECFP-cPLA2S505A_NP following_VBG ATP_NP and_CC IONO_NP stimulation_NN Cells_NP expressing_VBG ECFP-cPLA2S505A_NP and_CC EYFP-cPLA2_NP were_VBD stimulated_VBN with_IN ATP_NP and_CC IONO_NP ._SENT ECFP_NP and_CC EYFP_NP fluorescence_NN images_NNS were_VBD taken_VBN at_IN 3_CD s_JJ intervals_NNS ._SENT Representative_JJ frames_NNS from_IN time-lapse_NN images_NNS show_VBP the_DT distribution_NN of_IN EYFP-cPLA2_NP and_CC ECFP-cPLA2S505A_NP fluorescence_NN before_IN and_CC 30_CD s_NNS after_IN addition_NN of_IN 100_CD muM_NN ATP_NP ,_, followed_VBN by_IN addition_NN of_IN 10_CD muM_NN IONO_NP at_IN 1_CD min_NN (_( panels_NNS A_NP and_CC B_NP )_) ._SENT (_( C_LS )_) Fluorescent_JJ protein_NN (_( FP_NP )_) fluorescence_NN from_IN the_DT area_NN of_IN the_DT Golgi_NP (_( inset_NN )_) was_VBD analyzed_VBN with_IN respect_NN to_TO time_NN before_IN and_CC after_IN ATP_NP and_CC IONO_NP addition_NN (_( arrows_NNS )_) ._SENT (_( D_NP )_) Overlay_NP of_IN the_DT 75_CD s_JJ images_NNS from_IN panels_NNS A_NP and_CC B._NP Results_NNS are_VBP representative_JJ of_IN 5_CD independent_JJ experiments_NNS and_CC analysis_NN of_IN several_JJ cells_NNS per_IN experiment_NN ._SENT Figure_NP 6_CD |_SYM Translocation_NN of_IN ECFP-cPLA2S727A_NP following_VBG IONO_NP stimulation_NN Translocation_NN of_IN ECFP-cPLA2S727A_NP following_VBG IONO_NP stimulation_NN Cells_NP expressing_VBG ECFP-cPLA2S727A_NP and_CC EYFP-cPLA2_NP were_VBD stimulated_VBN with_IN IONO_NP ._SENT Representative_JJ frames_NNS from_IN time-lapse_NN images_NNS show_VBP the_DT distribution_NN of_IN EYFP-cPLA2_NP and_CC ECFP-cPLA2S727A_NP fluorescence_NN before_IN and_CC 13_CD s_NNS after_IN addition_NN of_IN 10_CD muM_NN IONO_NP (_( panels_NNS A_NP and_CC B_NP )_) ._SENT (_( C_LS )_) Fluorescent_JJ protein_NN (_( FP_NP )_) fluorescence_NN from_IN the_DT area_NN of_IN the_DT Golgi_NP (_( inset_NN )_) was_VBD analyzed_VBN with_IN respect_NN to_TO time_NN before_IN and_CC after_IN IONO_NP addition_NN (_( arrow_NN )_) ._SENT (_( D_NP )_) Overlay_NP of_IN the_DT 77_CD s_JJ images_NNS from_IN panels_NNS A_NP and_CC B._NP Results_NNS are_VBP representative_JJ of_IN 4_CD independent_JJ experiments_NNS and_CC analysis_NN of_IN several_JJ cells_NNS per_IN experiment_NN ._SENT The_DT MEK1/ERK_NP pathway_NN regulates_VBZ cPLA2_NN and_CC ERKs_NP phosphorylate_JJ cPLA2_NN on_IN Ser505_NP ._SENT The_DT results_NNS of_IN this_DT study_NN demonstrate_VBP that_IN this_DT pathway_NN is_VBZ required_VBN for_IN cPLA2-mediated_JJ AA_NP release_NN independent_JJ of_IN Ser505_NP phosphorylation_NN and_CC extend_VB our_PP$ previous_JJ work_NN in_IN macrophages_NNS by_IN demonstrating_VBG that_IN this_DT alternative_JJ role_NN of_IN the_DT MEK1/ERK_NP pathway_NN is_VBZ not_RB involved_VBN in_IN regulating_NN [_SYM Ca2+]i_NP change_NN or_CC cPLA2_JJ translocation_NN kinetics_NNS or_CC targeting_VBG ,_, but_CC is_VBZ required_VBN for_IN optimal_JJ hydrolytic_JJ activity_NN and_CC AA_NP release_NN ._SENT The_DT results_NNS shown_VBN here_RB demonstrate_VB that_DT inhibition_NN of_IN MEK_NP with_IN U0126_NP quantitatively_RB inhibits_VBZ both_DT ERK_NP phosphorylation_NN and_CC AA_NP release_NN in_IN MDCK_NP cells_NNS in_IN response_NN to_TO [_SYM Ca2+]i_NP mobilization_NN ._SENT The_DT MEK_NP inhibitor_NN PD098059_NP ,_, a_DT less_RBR potent_JJ inhibitor_NN ,_, also_RB inhibited_VBD ATP-_NP and_CC IONO-induced_NP AA_NP release_NN (_( data_NNS not_RB shown_VBN )_) ._SENT ERK_NN was_VBD found_VBN to_TO be_VB constitutively_RB phosphorylated_JJ in_IN our_PP$ study_NN using_VBG MDCK_NP cells_NNS from_IN ATCC_NP ,_, in_IN contrast_NN to_TO what_WP has_VBZ been_VBN reported_VBN previously_RB for_IN MDCK-D1_NP ,_, a_DT subclone_NN of_IN MDCK_NP selected_VBN for_IN adrenergic_JJ receptor_NN expression_NN ._SENT However_RB ,_, a_DT side-by-side_NN comparison_NN of_IN MDCK_NP cells_NNS from_IN ATCC_NP and_CC the_DT MDCK-D1_JJ subclone_NN (_( kindly_RB provided_VBN by_IN Dr._NP Paul_NP Insel_NP ,_, UCSD_NP )_) demonstrated_VBD constitutive_JJ activation_NN of_IN ERKs_NP when_WRB both_DT are_VBP grown_VBN at_IN low_JJ density_NN (_( not_RB shown_VBN )_) ._SENT However_RB ,_, at_IN high_JJ density_NN ERKs_NNS are_VBP less_RBR active_JJ and_CC can_MD be_VB further_RBR activated_VBN by_IN phorbol_NN ester_NN (_( not_RB shown_VBN )_) ._SENT In_IN MDCK-D1_JJ cells_NNS ,_, without_IN constitutively_RB active_JJ ERKs_NP ,_, AA_NP release_NN is_VBZ delayed_VBN after_RB [_SYM Ca2+]i_NP mobilization_NN ,_, and_CC is_VBZ temporally_RB correlated_VBN with_IN ERK_NP activation_NN ,_, whereas_IN in_IN MDCK_NP cells_NNS with_IN constitutively_RB active_JJ ERKs_NP ,_, AA_NP release_NN is_VBZ rapid_JJ ,_, with_IN significant_JJ AA_NP release_NN measured_VBD 30_CD s_NNS after_RB [_SYM Ca2+]i_NP increase_NN ._SENT This_DT temporal_JJ correlation_NN between_IN AA_NP release_NN and_CC ERK_NP activation_NN has_VBZ also_RB been_VBN reported_VBN in_IN CHO_NP cells_NNS in_IN response_NN to_TO PAF_NP stimulation_NN ._SENT These_DT results_NNS support_VBP the_DT observations_NNS made_VBD here_RB that_IN ERK_NP activity_NN is_VBZ required_VBN for_IN phospholipid_NN hydrolysis_NN independently_RB of_IN cPLA2_JJ translocation_NN ._SENT cPLA2-mediated_JJ AA_NP release_NN must_MD be_VB preceded_VBN by_IN translocation_NN of_IN the_DT enzyme_NN to_TO its_PP$ membrane_NN substrate_NN which_WDT is_VBZ a_DT Ca2+-dependent_JJ process_NN and_CC is_VBZ a_DT function_NN of_IN the_DT calcium-dependent_JJ lipid-binding_NN (_( C2_NP )_) domain_NN ._SENT cPLA2_NN translocates_VBZ primarily_RB to_TO Golgi_NP in_IN response_NN to_TO a_DT transient_NN [_SYM Ca2+]i_NP changes_NNS and_CC to_TO Golgi_NP and_CC ER_NP in_IN response_NN to_TO a_DT sustained_VBN [_SYM Ca2+]i_NP increase_NN ._SENT The_DT reduction_NN in_IN AA_NP release_NN by_IN MEK_NP inhibition_NN did_VBD not_RB involve_VB a_DT failure_NN in_RB [_SYM Ca2+]i_NP release_NN or_CC translocation_NN ._SENT These_DT results_NNS show_VBP that_IN translocation_NN is_VBZ necessary_JJ but_CC not_RB sufficient_JJ for_IN optimum_JJ hydrolytic_JJ activity_NN ._SENT Measuring_VBG cPLA2_JJ translocation_NN is_VBZ not_RB a_DT trivial_JJ matter_NN when_WRB investigating_VBG mechanisms_NNS of_IN AA_NP release_NN ._SENT For_IN example_NN ,_, cPLA2_JJ constructs_NNS with_IN a_DT S505A_NP mutation_NN have_VBP long_RB been_VBN recognized_VBN as_RB unable_JJ to_TO support_VB AA_NP release_NN in_IN response_NN to_TO physiological_JJ agonists_NNS or_CC low-dose_NN ionophore_NN when_WRB transfected_VBN in_IN cells_NNS ._SENT In_IN contrast_NN ,_, cPLA2_JJ S505A_NP is_VBZ active_JJ in_IN vitro_NN and_CC phosphorylation_NN only_RB modestly_RB increases_VBZ the_DT activity_NN of_IN the_DT enzyme_NN ._SENT Interestingly_RB ,_, the_DT inhibitory_JJ effect_NN of_IN the_DT S505A_NP mutation_NN on_IN AA_NP release_NN is_VBZ obviated_VBN by_IN a_DT high_NN [_SYM Ca2+]i_NP increase_NN ._SENT In_IN light_NN of_IN these_DT observations_NNS ,_, it_PP is_VBZ possible_JJ that_IN Ser505_NP phosphorylation_NN may_MD alter_VB the_DT [_SYM Ca2+]i_NP sensitivity_NN of_IN the_DT enzyme_NN ,_, its_PP$ rate_NN of_IN translocation_NN ,_, its_PP$ intracellular_JJ targeting_VBG or_CC ,_, as_RB has_VBZ been_VBN previously_RB suggested_VBN ,_, the_DT ability_NN of_IN cPLA2_NN to_TO release_VB from_IN a_DT non-membrane_NN sequestering_VBG agent_NN ._SENT Although_IN one_CD report_NN has_VBZ shown_VBN that_IN cPLA2_JJ S505A_NP translocates_VBZ in_IN CHO_NP cells_NNS in_IN response_NN to_TO ionophore_NN ,_, we_PP were_VBD able_JJ to_TO directly_RB compare_VB rates_NNS of_IN translocation_NN between_IN cPLA2_JJ and_CC cPLA2_JJ S505A_NP to_TO a_DT physiological_JJ agonist_NN and_CC found_VBD no_DT difference_NN between_IN translocation_NN rates_NNS or_CC intracellular_JJ targeting_VBG ._SENT We_PP also_RB demonstrated_VBD that_IN there_EX was_VBD no_DT difference_NN in_IN translocation_NN rates_NNS or_CC intracellular_JJ targeting_VBG between_IN wild-type_NN cPLA2_NN and_CC cPLA2_JJ S727A_NP ,_, which_WDT has_VBZ the_DT same_JJ phenotype_NN as_IN S505A_NP with_IN regard_NN to_TO AA_NP release_VB when_WRB transfected_JJ into_IN cells_NNS ._SENT Thus_RB ,_, the_DT role_NN of_IN cPLA2_JJ phosphorylation_NN in_IN mediating_VBG AA_NP release_NN remains_VBZ unclear_JJ ._SENT Although_IN the_DT alternative_JJ mechanism_NN whereby_WRB the_DT MEK1/ERK_NP pathway_NN regulates_VBZ cPLA2_NN is_VBZ not_RB known_VBN ,_, it_PP is_VBZ possible_JJ that_IN it_PP affects_VBZ membrane_NN properties_NNS and/or_CC cPLA2_JJ conformation_NN that_WDT promotes_VBZ optimal_JJ hydrolytic_JJ activity_NN ._SENT It_PP is_VBZ also_RB possible_JJ that_IN the_DT alternative_JJ mechanism_NN is_VBZ due_JJ to_TO phosphorylation_NN of_IN cPLA2_NN on_IN a_DT novel_JJ site_NN by_IN a_DT kinase_NN that_WDT is_VBZ downstream_JJ of_IN the_DT MEK1/ERK_NP pathway_NN or_CC phosphorylation_NN of_IN a_DT regulatory_JJ protein_NN ._SENT Translocation_NN to_TO membrane_NN is_VBZ a_DT critical_JJ regulatory_JJ step_NN for_IN the_DT action_NN of_IN cPLA2_NN because_IN it_PP is_VBZ necessary_JJ for_IN access_NN to_TO substrate_NN ._SENT In_IN this_DT study_NN we_PP demonstrate_VBP ,_, however_RB ,_, that_DT association_NN of_IN cPLA2_NN with_IN membrane_NN when_WRB phosphorylated_JJ on_IN Ser505_NP is_VBZ not_RB sufficient_JJ for_IN its_PP$ full_JJ activity_NN in_IN vivo_RB ._SENT This_DT is_VBZ demonstrated_VBN by_IN the_DT results_NNS showing_VBG that_DT inhibition_NN of_IN the_DT MEK1/ERK_NP pathway_NN significantly_RB blocks_VBZ AA_NP release_NN but_CC has_VBZ no_DT effect_NN on_RB [_SYM Ca2+]i_NP mobilization_NN or_CC cPLA2_JJ translocation_NN and_CC targeting_VBG ._SENT Diminution_NN of_IN AA_NP release_NN by_IN MEK1/ERK_NP is_VBZ also_RB independent_JJ of_IN cPLA2_JJ phosphorylation_NN on_IN Ser505_NP ._SENT Consequently_RB ,_, our_PP$ results_NNS demonstrate_VBP in_IN living_VBG cells_NNS that_IN the_DT translocation_NN process_NN and_CC subsequent_JJ catalytic_JJ activity_NN on_IN the_DT membrane_NN are_VBP two_CD independently_RB regulated_VBN steps_NNS ._SENT Fluorescent_JJ protein-cPLA2_JJ fusion_NN constructs_NNS |_SYM DNA_NN encoding_VBG the_DT full-length_JJ human_JJ cPLA2_NN was_VBD cloned_VBN into_IN the_DT vector_NN pEGFP-C3_NN (_( Clontech_NP )_) to_TO create_VB pEGFP-cPLA2_NN ,_, as_RB previously_RB described_VBN ._SENT The_DT XbaI/PstI_NP fragment_NN from_IN a_DT cPLA2alpha_NN clone_NN containing_VBG S505A_NP or_CC S727A_NP mutations_NNS was_VBD inserted_VBN into_IN an_DT XbaI/PstI_NP site_NN in_IN pEGFP-cPLA2_NN to_TO generate_VB pEGFP-cPLA2S505A_NN and_CC pECFP-cPLA2S727A_NN ._SENT Different_JJ fluorescent-protein_NN tagged_VBD constructs_NNS were_VBD produced_VBN by_IN exchanging_VBG the_DT NheI/BsrGI_NP fragment_NN containing_VBG the_DT fluorescent_JJ protein_NN coding_VBG sequence_NN between_IN EGFP_NP ,_, EYFP_NP ,_, and_CC ECFP_NP ._SENT All_DT constructs_NNS were_VBD confirmed_VBN by_IN sequencing_NP ._SENT Cell_NN culture_NN |_SYM MDCK_JJ cells_NNS obtained_VBN from_IN ATCC_NP were_VBD cultured_VBN in_IN DMEM_NP containing_VBG 10_CD %_NN FBS_NP ,_, 100_CD U/ml_NP penicillin_NN ,_, 100_CD mug/ml_NN streptomycin_NN ,_, 0.292_CD mg/ml_NN glutamine_NN (_( growth_NN medium_NN )_) in_IN 5_CD %_NN CO2_NN at_IN 37C_JJ ._SENT Subconfluent_JJ cells_NNS (_( 5_CD x_SYM 103_CD cells/cm2_NN )_) were_VBD transfected_VBN with_IN 2_CD mug_NN of_IN the_DT relevant_JJ plasmid_NN using_VBG Fugene-6_NP (_( Boehringer_NP Mannheim_NP )_) in_IN DMEM_NP containing_VBG 0.2_CD %_NN BSA_NP ,_, 100_CD U/ml_NP penicillin_NN ,_, 100_CD mug/ml_NN streptomycin_NN ,_, 0.292_CD mg/ml_NN glutamine_NN (_( serum-free_JJ medium_NN )_) following_VBG the_DT manufacturer_NN 's_POS protocol_NN ._SENT Stable_JJ lines_NNS expressing_VBG EGFP-cPLA2_NP were_VBD generated_VBN by_IN growing_VBG transfected_JJ cells_NNS in_IN growth_NN medium_NN for_IN 3_CD d_NN ,_, supplementing_VBG the_DT growth_NN medium_NN with_IN 5_CD mg/ml_NN Geneticin_NP (_( antibiotic_JJ G418-sulfate_NNS )_) ,_, and_CC culturing_VBG for_IN an_DT additional_JJ 2_CD wk_NN in_IN Geneticin_NP ._SENT Cells_NNS expressing_VBG EGFP_NP fluorescence_NN were_VBD selected_VBN using_VBG a_DT fluorescence-activated_JJ cell_NN sorter_NN ._SENT The_DT EGFP-positive_JJ cells_NNS were_VBD maintained_VBN in_IN growth_NN medium_NN supplemented_VBN with_IN 5_CD mg/ml_NN Geneticin_NP ._SENT For_IN imaging_NN studies_NNS ,_, MDCK_NP cells_NNS were_VBD plated_VBN on_IN glass-bottomed_JJ 35_CD mm_NN culture_NN dishes_NNS (_( MatTek_NP )_) at_IN 5_CD x_SYM 103_CD cells/cm2_NN in_IN growth_NN medium_NN and_CC incubated_VBD overnight_JJ ,_, transfected_JJ with_IN the_DT relevant_JJ plasmid(s)_NN ,_, changed_VBN into_IN serum-free_JJ medium_NN to_TO quiesce_VB the_DT cells_NNS ,_, incubated_VBD overnight_JJ ,_, and_CC used_VBD the_DT next_JJ day_NN ._SENT Immunoblotting_NN |_SYM Stable_JJ EGFP-cPLA2_NP transfectants_NNS were_VBD grown_VBN on_IN 100_CD mm_NN dishes_NNS at_IN 5_CD x_SYM 103_CD cells/cm2_NN in_IN growth_NN medium_NN for_IN one_CD day_NN ,_, then_RB quiesced_VBN in_IN serum-free_JJ medium_NN overnight_RB ._SENT Cells_NNS were_VBD scraped_VBN into_IN ice-cold_JJ lysis_NN buffer_NN :_: 50_CD mM_NP HEPES_NP ,_, pH_NN 7.4_CD ,_, 150_CD mM_NP sodium_NN chloride_NN ,_, 1.5_CD mM_NP magnesium_NN chloride_NN ,_, 10_CD %_NN glycerol_NN ,_, 1_CD %_NN Triton_NP X-100_NP ,_, 1_CD mM_NP EGTA_NP ,_, 200_CD muM_NN sodium_NN vanadate_NN ,_, 10_CD mM_NP tetrasodium_NN pyrophosphate_NN ,_, 100_CD mM_NP sodium_NN fluoride_NN ,_, 10_CD mug/ml_NN leupeptin_NN ,_, and_CC 10_CD mug/ml_NN aprotinin_NN ._SENT Lysates_NNS were_VBD centrifuged_VBN at_IN 15,000_CD x_NN g_NN for_IN 15_CD min_NN ,_, and_CC protein_NN concentration_NN of_IN the_DT supernatant_JJ was_VBD determined_VBN by_IN the_DT bicinchoninic_JJ acid_NN method_NN ._SENT Laemmli_NP electrophoresis_NN sample_NN buffer_NN (_( 5x_NP )_) was_VBD added_VBN to_TO the_DT lysates_NNS ,_, and_CC SDS-polyacrylamide_NP gel_NN electrophoresis_NN and_CC immunoblotting_NN were_VBD performed_VBN using_VBG 35_CD mug_NN lysate_NN protein_NN ,_, phospho-specific_JJ antibodies_NNS for_IN ERK_NP and_CC p38_NP ,_, and_CC rabbit_VB polyclonal_JJ antibody_NN for_IN cPLA2_NN ._SENT Dual_JJ imaging_NN microscopy_NN of_IN fluorescent_JJ protein_NN translocation_NN |_SYM In_IN order_NN to_TO compare_VB the_DT characteristics_NNS of_IN full-length_JJ cPLA2_NN and_CC cPLA2S505A_NN or_CC cPLA2S727A_NN translocation_NN ,_, while_IN controlling_VBG for_IN cell-to-cell_NN heterogeneity_NN ,_, we_PP used_VBD a_DT dual_JJ CFP/YFP_NP imaging_NN approach_NN ._SENT EYFP-cPLA2/ECFP-cPLA2S505A-_NP or_CC pECFP-cPLA2S727A-transfected_JJ MDCK_JJ cells_NNS grown_VBN on_IN MatTek_NP plates_NNS were_VBD quiesced_VBN overnight_RB in_IN serum-free_JJ medium_NN ,_, washed_VBN with_IN and_CC incubated_VBN in_IN Hank_NP 's_POS balanced_JJ salt_NN solution_NN (_( HBSS_NP )_) additionally_RB buffered_VBD with_IN 25_CD mM_NP HEPES_NP pH_NN 7.4_CD (_( HHBSS_NP )_) ._SENT Cells_NNS were_VBD imaged_VBN using_VBG an_DT Olympus_NP inverted_JJ microscope_NN equipped_VBN with_IN a_DT 60x_NP ,_, 1.25_CD NA_NP oil_NN immersion_NN objective_NN ,_, CFP_NP and_CC YFP_NP emission_NN filters_NNS (_( Chroma_NP )_) in_IN a_DT Sutter_NP filter_NN wheel_NN ,_, a_DT dual_JJ CFP/YFP_NP dichroic_JJ mirror_NN ,_, and_CC a_DT TILL_NP Imago_NP CCD_NP camera_NN (_( TILL_NP Photonics_NP )_) ._SENT Excitation_NN light_NN of_IN 430_CD and_CC 510_CD nm_NN for_IN CFP_NP and_CC YFP_NP ,_, respectively_RB ,_, was_VBD provided_VBN using_VBG a_DT Polychrome_NP IV_NP monochromator_NN (_( TILL_NP Photonics_NP )_) ._SENT TILLvisION_NN software_NN was_VBD used_VBN for_IN acquisition_NN and_CC analysis_NN ._SENT Bleach_NN values_NNS for_IN ECFP_NP and_CC EYFP_NP were_VBD calculated_VBN by_IN determining_VBG the_DT background-corrected_NN fluorescence_NN for_IN the_DT entire_JJ cell_NN with_IN respect_NN to_TO time_NN and_CC normalizing_VBG each_DT value_NN to_TO the_DT initial_JJ value_NN ._SENT ECFP/EYFP_JJ fluorescence_NN changes_NNS with_IN respect_NN to_TO time_NN for_IN regions_NNS of_IN interest_NN corresponding_JJ to_TO an_DT area_NN of_IN Golgi_NP membrane_NN were_VBD determined_VBN by_IN calculating_VBG the_DT Ft/F0_NP ,_, where_WRB Ft_NP is_VBZ the_DT background-_NN and_CC bleach-corrected_JJ ECFP_NP or_CC EYFP_NP fluorescence_NN at_IN time_NN =_SYM t_NN and_CC F0_NP is_VBZ the_DT background-corrected_JJ ECFP_NP or_CC EYFP_NP fluorescence_NN at_IN time_NN =_SYM 0_CD s._NP Fluorescence_NP was_VBD normalized_VBN to_TO the_DT F0_NP value_NN ,_, which_WDT resulted_VBD in_IN Ft/F0_NP representing_VBG the_DT fraction_NN of_IN total_JJ cell_NN fluorescence_NN at_IN Golgi_NP ._SENT Final_JJ images_NNS were_VBD produced_VBN using_VBG Adobe_NP Photoshop_NP ._SENT Calcium_NN imaging_NN |_SYM MDCK_JJ cells_NNS grown_VBN on_IN MatTek_NP plates_NNS were_VBD quiesced_VBN overnight_RB in_IN serum-free_JJ medium_NN ,_, washed_VBN with_IN HHBSS_NP containing_VBG 1_CD mM_NP probenecid_NN and_CC incubated_VBN with_IN 5_CD muM_NN Fura2-AM_NP (_( Calbiochem_NP )_) in_IN HHBSS_NP ,_, 1_CD mM_NP probenecid_NN ,_, and_CC 1_CD %_NN DMSO_NP for_IN 45_CD min_NN at_IN 37C_JJ ._SENT Cells_NNS were_VBD then_RB washed_VBN with_IN HHBSS_NP containing_VBG 1_CD mM_NP probenecid_NN and_CC imaged_VBN after_IN a_DT 30_CD min_NN incubation_NN for_IN de-esterification_NN of_IN the_DT Fura2-AM_NP ._SENT Single-cell_NN imaging_NN was_VBD performed_VBN on_IN the_DT Olympus_NP system_NN described_VBD above_IN ,_, but_CC using_VBG a_DT 40x_NN ,_, 1.35_CD NA_NP oil_NN immersion_NN objective_NN and_CC a_DT Fura2_NP dichroic_JJ mirror_NN and_CC emission_NN filter_NN (_( Chroma_NP )_) ._SENT Fura2_JJ image_NN pairs_NNS illuminated_VBN at_IN 340_CD and_CC 380_CD nm_NN were_VBD taken_VBN at_IN 1_CD Hz_NP ._SENT The_DT [_SYM Ca2+]i_NP increase_NN is_VBZ expressed_VBN as_IN the_DT ratio_NN of_IN the_DT background-corrected_JJ Fura2_JJ fluorescence_NN at_IN 340_CD and_CC 380_CD nm_NN ._SENT Measurement_NN of_IN AA_NP release_NN |_SYM The_DT protocol_NN for_IN determining_VBG AA_NP release_NN is_VBZ essentially_RB as_RB described_VBN ._SENT MDCK_NN cells_NNS stably_RB expressing_VBG EGFP-cPLA2_NP were_VBD plated_VBN in_IN 12-well_NP plates_NNS at_IN 5_CD x_SYM 103_CD cells/cm2_NN and_CC incubated_VBN in_IN growth_NN medium_NN overnight_RB ._SENT Cells_NNS were_VBD then_RB washed_VBN twice_RB with_IN serum-free_JJ medium_NN and_CC incubated_VBN with_IN 0.25_CD muCi_NNS [_SYM 3H]-AA/well_JJ in_IN serum-free_JJ medium_NN overnight_RB ._SENT U0126_NN or_CC vehicle_NN was_VBD added_VBN to_TO each_DT well_NN and_CC the_DT cells_NNS were_VBD then_RB incubated_VBN for_IN 15_CD min_NN at_IN 37C_JJ in_IN 5_CD %_NN CO2_NN ._SENT Cells_NNS were_VBD washed_VBN to_TO remove_VB unincorporated_JJ [_SYM 3H]-AA_JJ and_CC then_RB incubated_VBN in_IN HHBSS_NP supplemented_VBD with_IN 0.05_CD %_NN BSA_NP with_IN either_DT U0126_NN or_CC vehicle_NN ._SENT Cells_NNS were_VBD stimulated_VBN with_IN the_DT agonist_NN of_IN choice_NN and_CC the_DT medium_NN was_VBD collected_VBN at_IN appropriate_JJ time_NN points_NNS ._SENT The_DT medium_NN was_VBD centrifuged_VBN at_IN 500_CD g_NN for_IN 5_CD min_NN ,_, and_CC the_DT amount_NN of_IN radioactivity_NN in_IN the_DT supernatant_JJ was_VBD determined_VBN by_IN scintillation_NN counting_NN ._SENT Cells_NNS were_VBD scraped_VBN in_IN 0.5_CD ml_NN 0.1_CD %_NN Triton_NP X-100_NP for_IN determining_VBG the_DT total_JJ cellular_JJ radioactivity_NN ._SENT JHE_NP carried_VBD out_RP the_DT Ca_NP and_CC FP_NP imaging_NN studies_NNS ,_, participated_VBN in_IN the_DT design_NN and_CC coordination_NN of_IN the_DT study_NN ,_, and_CC drafted_VBD the_DT manuscript_NN ._SENT DJF_NP performed_VBD the_DT AA_NP release_NN and_CC Western_JJ blot_NN studies_NNS and_CC participated_VBD in_IN the_DT design_NN and_CC coordination_NN of_IN the_DT study_NN ._SENT CCL_NP conceived_VBD of_IN the_DT study_NN ,_, participated_VBN in_IN its_PP$ desi_NNS 